I’m back with another semi-regular column tracking the ups and downs in small-cap biotech. Today, I take a look at Fennec Pharma (FENC) and Actinium Pharma (ATNM). As a reminder, I’m taking requests for companies to cover, so reach out to me on Twitter (DMs are open), email, or in the comment section of the column.
Dr. Andrew Hong, a pediatric oncologist and instructor at Harvard Medical School, has mixed feelings about cisplatin, a commonly used platinum-based chemotherapy. The drug is highly effective, even curative, for children diagnosed with a variety of solid tumors. But cisplatin is also extremely toxic to the inner ear, so many of Hong’s young patients end up with profound and permanent hearing loss.
“As physicians, we want to achieve a cure for our patients. That will always be our main focus,” said Hong. But hearing loss in children is particularly debilitating, which makes the use of cisplatin a difficult trade-off, he added.
Company ideas for your column: MRKR, HROW, CBAY, ARQL, ARWR, KALV, ACER, CATB, AUPH. Best regards
Comments are closed.